Kinase inhibitors: a new class of antirheumatic drugs
Vasileios C KyttarisDivision of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. How...
Saved in:
Main Author: | Kyttaris VC (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease-modifying antirheumatic drugs - Old and new: A brief overview
by: Vidya Divakar Baliga, et al.
Published: (2019) -
Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study
by: Masahiko Miyashiro, et al.
Published: (2024) -
Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials
by: Tatjana Welzel, et al.
Published: (2021) -
Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023) -
Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials
by: Tatjana Welzel, et al.
Published: (2021)